SEARCH RESULTS

329963 RESULTS

Prednisone

THERAPEUTICS Small Molecule Inflammation The Alzheimer's Disease Cooperative Study conducted a multicenter trial of 138 patients with Alzheimer's disease who were randomized to take placebo or 20 mg predisone per day for a month, followed by 10 mg daily for

AQW051

THERAPEUTICS Novartis Pharmaceuticals Corporation Alpha-7 nicotinic acetylcholine receptor agonist Small Molecule Cholinergic System Phase 1 for this compound was conducted in Japan but no further development in this country has been reported. Development of AQW 051 f

ABT-089

THERAPEUTICS Abbott Laboratories Small Molecule Cholinergic System Alzheimer's Disease Discontinued Breaking News

HF0220

THERAPEUTICS Newron Small Molecule Inflammation Alzheimer's Disease Discontinued Breaking News

GSK239512

THERAPEUTICS GlaxoSmithKline (GSK) Small Molecule Cholinergic System Other Neurotransmitters Between 2007 and 2014, GSK conducted six clinical trials on this compound, three in Alzheimer's, two in multiple sclerosis, and one in schizophrenia. Phase 1 studies asse

ABT-288

THERAPEUTICS AbbVie Small Molecule Cholinergic System Other Neurotransmitters Three clinical trials are registered on this compound. A single- and multiple-ascending dose study in healthy volunteers was reported to have been generally safe and well-tolerated, with the

Lornoxicam

THERAPEUTICS JSW Lifesciences Small Molecule Inflammation Pain in US Alzheimer's Disease Discontinued Mild Cognitive Impairment Discontinued Breaking News

Acitretin

THERAPEUTICS Actavis Allergan plc Soriatane Neotigason RO 101670 Small Molecule Amyloid-Related In 2010, a Phase 2 trial began at two sites, in Mainz and Rostock, Germany. It aimed to investigate efficacy and tolerability of a four-week course of 30 mg/day of acitreti

ABT-384

THERAPEUTICS AbbVie Small Molecule Other In 2009 and 2010, Abbvie conducted two phase 1 studies to evaluate safety, pharmacokinetics and-dynamics in healthy and elderly participants (Liu et al., 2013;  Katz et al., 2013). Between May 2010 and July 2011, Abbvie ran a m

Intepirdine

THERAPEUTICS Axovant Sciences Ltd. RVT-101 SB 742457 GSK 742457 Small Molecule Other Neurotransmitters Several Phase 1 studies compared SB-742457 in capsule and tablet formulations, and showed that the compound was well-tolerated. GSK completed four Phase 2 studies of

Ketasyn

THERAPEUTICS Cerecin Pte. Ltd. Axona Caprylic Acid AC-1202 Supplement, Dietary Other A two-week open-label safety, tolerability, and pharmacokinetics study of different formulations of Ketasyn in 60 healthy elderly volunteers preceded two Phase 2 studies. From 2004 to

Current Filters

No filters selected

Filter By

DATE RANGE
  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From
      To

TYPE